TECOS

The TECOS CVOT assessed the cardiovascular safety of sitagliptin in patients with type 2 diabetes and prior CV disease. This module details the results.

TECOS

TECOS
Login or create an account to see restricted content
TECOS: trial design
Login or create an account to see restricted content
TECOS: baseline characteristics
Login or create an account to see restricted content
TECOS: CV disease at baseline
Login or create an account to see restricted content
TECOS: renal function at baseline
Login or create an account to see restricted content
TECOS: glucose-lowering medication and CV medication at baseline
Login or create an account to see restricted content
TECOS: 4P-MACE primary outcome
Login or create an account to see restricted content
TECOS: other CV and mortality outcomes
Login or create an account to see restricted content
TECOS: changes in eGFR over 4 years
Login or create an account to see restricted content
TECOS: safety overview
Login or create an account to see restricted content
TECOS: summary

TECOS

TECOS

TECOS: trial design

TECOS: baseline characteristics

TECOS: CV disease at baseline

TECOS: renal function at baseline

TECOS: glucose-lowering medication and CV medication at baseline

TECOS: 4P-MACE primary outcome

TECOS: other CV and mortality outcomes

TECOS: changes in eGFR over 4 years

TECOS: safety overview

TECOS: summary